InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | 2026-04-20 | Oliveto Joseph | Director & President and CEO | Sale | 36.5K | $2.26 | $82K | 446.2K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $1.5M | $0-100.0% | $1.0M-80.0% | $5.0M |
| Research and development, net of tax credits | $18.1M+26.1% | $14.4M-53.8% | $31.1M-22.0% | $39.8M |
| General and administrative | $17.3M+3.2% | $16.7M+5.1% | $15.9M+1.4% | $15.7M |
| Commercial | $28.3M+157.2% | $11.0M-27.2% | $15.1M+66.2% | $9.1M |
| Loss from operations | -$62.1M-47.6% | -$42.1M+31.1% | -$61.1M-2.4% | -$59.6M |
| Interest income | $2.9M-29.9% | $4.2M+5.0% | $4.0M+216.3% | $1.3M |
| Interest expense | -$3.8M-7.2% | -$3.6M-40.2% | -$2.6M | — |
| Net loss and comprehensive loss | -$63.1M-51.9% | -$41.5M+30.4% | -$59.7M-2.2% | -$58.4M |
| Weighted average number of shares and pre-funded warrants outstanding, basic (in shares) | $83.88B+34.8% | $62.21B+44.8% | $42.96B+1.2% | $42.45B |
| Weighted average number of shares and pre-funded warrants outstanding, diluted (in shares) | $83.88B+34.8% | $62.21B+44.8% | $42.96B+1.2% | $42.45B |
| Net loss per share, basic (in dollars per share) | -$750-11.9% | -$670+51.8% | -$1K-0.7% | -$1K |
| Net loss per share, diluted (in dollars per share) | -$750-11.9% | -$670+51.8% | -$1K-0.7% | -$1K |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)